2009
DOI: 10.1111/j.1365-2230.2008.02842.x
|View full text |Cite
|
Sign up to set email alerts
|

Trichomegaly of the eyelashes following treatment with cetuximab

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
16
0

Year Published

2009
2009
2020
2020

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 26 publications
(16 citation statements)
references
References 5 publications
0
16
0
Order By: Relevance
“…[8,12,15,16,19] Mucocutaneous reactions to EGFR inhibitors are summarized in table I. [1][2][3][4][5][6]9,11,14,15,17,19,20,[22][23][24][25][26][27][28][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] These include not only increased (hypertrichosis) and decreased (alopecia) Acral fissures Fissures occur on the hands and feet, fingers (tips and interphalangeal joints), and toes. [8,15,26] Indeed, the papulopustular eruption has been associated with favorable tumor response, lengthening of time to progression, and improved overall survival.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…[8,12,15,16,19] Mucocutaneous reactions to EGFR inhibitors are summarized in table I. [1][2][3][4][5][6]9,11,14,15,17,19,20,[22][23][24][25][26][27][28][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] These include not only increased (hypertrichosis) and decreased (alopecia) Acral fissures Fissures occur on the hands and feet, fingers (tips and interphalangeal joints), and toes. [8,15,26] Indeed, the papulopustular eruption has been associated with favorable tumor response, lengthening of time to progression, and improved overall survival.…”
Section: Discussionmentioning
confidence: 99%
“…Acquired eyelash trichomegaly has been described in individuals in whom the elongation of their eyelashes is associated with either systemic disease or infection, topical or systemic drug treatment, or an underlying cancer. [1,4,5,36,38] Trichomegaly of the eyelashes has also been reported in patients treated with other monoclonal antibodies to EGFR such as panitumumab. [1][2][3][4][5]14,24,[36][37][38][39][40][41] The drug is usually delivered at an initial dose of 400 mg m 2 followed by weekly infusions of 250 mg m 2 ; [1,3,4] the patients may also be receiving radiotherapy [3] or irinotecan.…”
Section: Miscellaneousmentioning
confidence: 95%
See 1 more Smart Citation
“…Dermatologic side effects of cetuximab include acneiform eruptions, seborrhoeic-like dermatitis, trichomegaly, eczema, xerosis, desquamation, paronychia, hair changes, telangiectasia and hyperpigmentation Suh et al, 2006;Vaccaro, 2008). Acneiform skin eruption is the most common adverse event of cetuximab therapy with an incidence of about 80 % (Gutzmer et al, 2005;.…”
Section: Case Reportmentioning
confidence: 99%
“…It is also found in many human cancers including those of the head and neck, colon and rectum. EGFR leads to tumour growth, increased resistance to chemotherapy or radiotherapy, and metastasis formation (Vaccaro, 2008).…”
Section: Case Reportmentioning
confidence: 99%